Streetbeat News

Analyst Ratings

MEG

Needham analyst James Ricchiuti has reiterated a Buy rating for Montrose Environmental Group (NYSE:MEG) and maintained a price target of $54.

Portfolio Pulse from Benzinga Newsdesk

October 03, 2024 | 11:00 am

IMMX

HC Wainwright & Co. has reiterated its Buy rating on Immix Biopharma (NASDAQ:IMMX) and maintained a price target of $7, indicating confidence in the company's future performance.

Portfolio Pulse from Benzinga Newsdesk

October 03, 2024 | 10:57 am

AAP

LNW

MMYT

The article highlights three oversold consumer discretionary stocks with potential for short-term gains: Light & Wonder Inc (LNW), MakeMyTrip Ltd (MMYT), and Advance Auto Parts, Inc. (AAP). These stocks have RSI values below 30, indicating they are oversold and may present buying opportunities.

Portfolio Pulse from Avi Kapoor

October 03, 2024 | 10:55 am

BIGC

Needham analyst Scott Berg has reiterated a Buy rating for BigCommerce Holdings (NASDAQ:BIGC) and maintained a price target of $14.

Portfolio Pulse from Benzinga Newsdesk

October 03, 2024 | 10:52 am

ATLX

HC Wainwright & Co. has maintained a Buy rating on Atlas Lithium (NASDAQ:ATLX) but has lowered the price target from $41 to $19.

Portfolio Pulse from Benzinga Newsdesk

October 03, 2024 | 9:48 am

ENOV

JMP Securities has initiated coverage on Enovis (NYSE:ENOV) with a Market Outperform rating and set a price target of $62.

Portfolio Pulse from Benzinga Newsdesk

October 03, 2024 | 9:43 am

VRCA

Needham analyst Serge Belanger has downgraded Verrica Pharmaceuticals from Buy to Hold, while maintaining a $12 price target.

Portfolio Pulse from Benzinga Newsdesk

October 03, 2024 | 9:33 am

STZ

Constellation Brands (NYSE:STZ) is set to release its Q2 earnings, with expectations of $4.08 EPS and $2.9 billion in revenue. The company revised its FY25 EPS forecast slightly upwards. Analysts have maintained positive ratings, with some adjusting price targets.

Portfolio Pulse from Avi Kapoor

October 03, 2024 | 8:44 am

ANGO

AngioDynamics, Inc. (NASDAQ:ANGO) is set to release its Q1 earnings on Oct. 3, with analysts expecting a loss of 15 cents per share and revenue of $67.93 million. The company recently received CE Mark approval for its Auryon System in Europe. Analysts have mixed ratings, with price targets ranging from $10 to $14.

Portfolio Pulse from Avi Kapoor

October 03, 2024 | 7:37 am

HUM

B of A Securities has downgraded Humana from Neutral to Underperform and lowered its price target from $376 to $247.

Portfolio Pulse from Benzinga Newsdesk

October 02, 2024 | 10:03 pm